VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2022 | Real-world monitoring of ctDNA reliably predicts cancer recurrence in resected stages I-III CRC

Stacey Cohen, MD, University of Washington, Seatlle, WA, provides an overview of a retrospective analysis of a real-world cohort U.S-based multi-institutional study. Data from circulating tumor DNA (ctDNA) testing of over 16,0000 patients with stage I-III patients with colorectal cancer (CRC) were analyzed. Complete clinical information was available for approximately 400 patients, which demonstrated that post-operative MRD-negative status was associated with significantly higher recurrence-free survival (RFS) compared to MRD-positive. These results show ctDNA can reliably predict cancer recurrence in patients with resected stages I-III colorectal cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter